F2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug.
F2G and Shionogi released positive Phase 3 data on Thursday morning, giving the companies a potentially clear path to approval for their antifungal drug.
The …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer…
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into…
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. | After a…
Three-quarters of patients had a clinical response in mid-stage study
Shionogi won FDA approval for Xocova, an oral antiviral to prevent Covid-19 after exposure in people 12 and older who've been in…
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas…
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
I risultati dello studio clinico pivotale di Fase 3 frontMIND di Incyte sulla combinazione di Tafasitamab (Monjuvi®/Minjuvi®) presentati in occasione della sessione plenaria del congresso 2026 della European Hematology Association (EHA)...
